Nan (ln) Li bought ODTX once, on May 11, 2026

Li Nan (often cited publicly as Nan Li) is a founder and managing partner at Dimension Capital, a life sciences–focused investment firm, and serves as a director on the Board of Odyssey Therapeutics, Inc. (NASDAQ: ODTX).( In connection with Odyssey Therapeutics’ oversubscribed $213 million Series D financing to advance its clinical pipeline for autoimmune diseases, Nan Li joined the company’s Board of Directors as a representative of Dimension Capital, reflecting a significant role in guiding Odyssey’s strategy and growth as a corporate insider.(

At Dimension Capital, Li leads investments in innovative biopharmaceutical and life sciences companies, partnering with management teams to support drug development and commercialization across multiple therapeutic areas.( His board role at Odyssey Therapeutics extends that investment focus into active corporate governance, where he helps oversee capital allocation, clinical development priorities, and long‑term value creation for shareholders.( Through this combination of leadership at Dimension Capital and directorship at Odyssey Therapeutics, Li Nan plays a key role in financing and shaping emerging biotech companies at the clinical stage.(

Written by Perplexity from public sources.